HA-1004二盐酸盐 | 91742-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: HA-1004二盐酸盐
• 英文名称: N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide
• 英文别名: 2-[2-(isoquinolin-5-ylsulfonylamino)ethyl]guanidine
• CAS: 91742-10-8
• 化学式: C₁₂H₁₅N₅O₂S
• 分子量: 293.35
• InChiKey: MZNDNBFMSVMUCX-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  HA-1004二盐酸盐 生成 HA 1004 盐酸盐
  参考文献：
  名称：

  HIDAKA, HIROYOSHI;SONE, TAKANORI

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-氨乙基)-5-异喹啉磺酰二盐酸盐 、 O-甲基异脲 半硫酸盐 生成 HA-1004二盐酸盐
  参考文献：
  名称：

  HIDAKA, HIROYOSHI;SONE, TAKANORI

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-(2-氨乙基)-5-异喹啉磺酰二盐酸盐 、 水 、 S-甲基异硫脲硫酸盐 、 sodium hydroxide 在 甲醇 、 HA-1004二盐酸盐 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以obtained in Referential example 1的产率得到HA-1004二盐酸盐
  参考文献：
  名称：

  Isoquinolinesulfonamide derivatives

  摘要：

  本发明涉及一种新型异喹啉磺酰胺衍生物，其化学式为(I)：##STR1## 其中，A为C.sub.0-10烷基或具有C.sub.1-10烷基、苯基、取代苯基或苯基烷基的C.sub.0-10烷基；R.sub.1和R.sub.2各为氢原子；或R.sub.1和R.sub.2直接连接形成未取代或取代有C.sub.1-4烷基的乙烯基；R.sub.3和R.sub.4各为氢原子、C.sub.1-6烷基或直接连接形成C.sub.2-6烷基；以及其药学上可接受的酸加成盐，以及制备它们的方法。该异喹啉衍生物具有舒张血管平滑肌和增加血流的作用，可用作血管扩张剂和降压剂。

  公开号：

  US04709032A1

文献信息

• Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or pertidomimetics
  申请人：Livnah Nurit

  公开号：US20050026840A1

  公开（公告）日：2005-02-03

  The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.

  本发明提供了具有高亲和力与蛋白激酶的ATP结合位点结合的小分子，这些小分子与模拟PKB底物的肽或肽类似物结合。根据本发明的嵌合化合物优选作为具有改进活性和选择性的PKB抑制剂。新型ATP类似物化合物，特别是异喹啉衍生物，与肽或肽类似物结合，可用作蛋白激酶的抑制剂，用于实验、医学和药物设计目的。此外，包括这些蛋白激酶抑制剂的药物组合物，以及使用这些组合物用于治疗和诊断癌症、糖尿病、心血管病变、出血性休克、肥胖症、炎症性疾病、中枢神经系统疾病和自身免疫疾病的方法也被揭示。
• Protein kinase inhibitors
  申请人：——

  公开号：US20040019077A1

  公开（公告）日：2004-01-29

  Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.

  本发明揭示了一种新颖的异喹啉衍生物，可用作蛋白激酶的抑制剂，用于实验、医学和药物设计目的。还揭示了特定的蛋白激酶B抑制剂优选化合物。此外，还揭示了包含这些蛋白激酶抑制剂的药物组合物，以及使用这些组合物治疗和诊断癌症、糖尿病、心血管病变、出血性休克、肥胖症、炎症性疾病、中枢神经系统疾病和自身免疫疾病的方法。
• Pharmaceutical agent containing Rho kinase inhibitor
  申请人：——

  公开号：US20020032148A1

  公开（公告）日：2002-03-14

  A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug. In addition, the Rho kinase inhibitor is provided as a reagent and a diagnostic.

  提供了一种新型药物代理——Rho激酶抑制剂，特别用于治疗高血压、心绞痛、脑血管收缩抑制剂、哮喘、周围循环障碍的治疗剂、早产预防剂、动脉硬化的治疗剂、抗癌药物、抗炎剂、免疫抑制剂、自身免疫疾病的治疗剂、抗艾滋病药物、避孕药、消化道感染预防剂、骨质疏松症的治疗剂、视网膜病的治疗剂和脑功能改善药物。此外，Rho激酶抑制剂还可作为试剂和诊断工具。
• Method for measuring glycosyltransferase activity
  申请人：Mount Sinai Hospital Corporation

  公开号：US05501957A1

  公开（公告）日：1996-03-26

  A method of assaying for glycosyltransferase activity in a sample. In a first step, a sample is reacted with a first sugar donor and an acceptor substrate to produce a transferase product. The first sugar donor and acceptor substrate are selected such that the sugar from the first sugar donor is capable of being transferred to the acceptor substrate in the presence of the glycosyltransferase to be assayed. In a second step, the transferase product is reacted with a second sugar donor having a sugar which is labelled with a labelling agent and an enzyme which is capable of transferring the sugar from the second sugar donor to the transferase product to produce a labelled transferase product and which has a higher affinity for the glycosyltransferase product compared to the affinity of the glycosyltransferase for the acceptor substrate. The labelling agent activity of the labelled transferase product or unreacted second sugar donor is assayed to determine transferase activity in the sample. A kit for assaying for glycosyltransferase activity in a sample is also described.

  一种在样品中检测糖基转移酶活性的方法。首先，将样品与第一种糖供体和受体底物反应，产生转移酶产物。第一种糖供体和受体底物被选择为第一种糖供体的糖在糖基转移酶存在下能够转移到受体底物。其次，将转移酶产物与第二种糖供体反应，该糖含有标记试剂，酶能够将第二种糖供体的糖转移到转移酶产物上，产生带标记的转移酶产物。该酶对糖基转移酶产物的亲和力高于对受体底物的亲和力。测定带标记的转移酶产物或未反应的第二种糖供体的标记试剂活性，以确定样品中的转移酶活性。还描述了用于检测样品中糖基转移酶活性的试剂盒。
• Isoquinolinesulfonamide derivatives and process for the preparation thereof
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0109023A1

  公开（公告）日：1984-05-23

  This invention relates to novel isoquinolinesulfonamide derivates of Formula (I): wherein A is a C0-10 alkylene group or a C0-10 alkylene group having a C1-10 alkyl group, a phenyl group, a substituted phenyl group or a phenylalkyl group; R1 and R2 each is a hydrogen atom; or R1 and R2 are linked directly to form an ethylene group unsubstituted or substituted with a C1-4 alkyl group; R3 and R4 each is a hydrogen atom, a C1-6 alkyl group or linked directly to form a C2-6 alkylene group; and the pharmaceutically acceptable acid addition salt thereof, and to a precess for preparing them. The isoquinoline derivatives possess a relaxatory action for vascular smooth muscle and action for increasing blood flow and are useful as a vasodilator and a hypotensor.

  本发明涉及式(I)的新型异喹啉磺酰胺衍生物： 其中 A 为 C0-10 烯基或具有 C1-10 烷基的 C0-10 烯基、苯基、取代苯基或苯基烷基；R1 和 R2 各为氢原子；或 R1 和 R2 直接连接形成未取代或被 C1-4 烷基取代的乙烯基； R3和R4各自为氢原子、C1-6烷基或直接连接形成C2-6亚烷基；及其药学上可接受的酸加成盐，以及制备它们的预处理方法。异喹啉衍生物具有松弛血管平滑肌和增加血流量的作用，可用作血管扩张剂和降压剂。